Recent Updates
Recently added Catalysts
OBIO Positive Sentiment Score: 75/100

Orchestra BioMed to Present at the Jefferies Global Healthcare Conference

Key Takeaway: Orchestra BioMed Holdings, Inc. will present at the Jefferies Global Healthcare Conference on June 8, 2023, in New York. Company management will be available for one-on-one meetings during the event. The company's forward-looking statements indicate potential growth and opportunities, although they acknowledge inherent uncertainties in their forecasts. A replay of the presentation will be accessible for 90 days following the event, providing further engagement for interested stakeholders.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Orchestra BioMed announces a corporate presentation at a significant healthcare conference.
  • The company's management will be available for one-on-one meetings, fostering collaboration.
  • The webcast of the presentation will be available for 90 days, enhancing accessibility.

Full Press Release Details

NEW HOPE, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 7-9, 2023.
Details of the presentation are shown below.
Format: Corporate presentation
Date: Thursday, June 8, 2023
Time: 2:30 PM ET (Track 6)
A replay of the webcast will be available on the Events section of the Orchestra BioMed website for 90 days following the presentation.
About Orchestra BioMed
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including, without limitation, statements relating to the Company’s ability to successfully execute on its late-stage development programs and identify new potential opportunities. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. The Company cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those identified in Part II, “Item 1A. Risk Factors” of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on May 12, 2023, and in the Company’s other filings with the SEC. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for the Company’s management to predict all risk factors, nor can they assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “the Company believes” and similar statements reflect the Company’s beliefs and opinions on the relevant subject. These statements are based upon information available to the Company as of the date hereof and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and the Company’s statements should not be read to indicate that it has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Frequently Asked Questions

When is the Orchestra BioMed presentation at the conference?

The presentation is on June 8, 2023, at 2:30 PM ET.

Where can I watch the Orchestra BioMed presentation?

The presentation can be viewed via webcast at Orchestra BioMed's website.

How long will the webcast replay be available?

A replay of the webcast will be accessible for 90 days post-presentation.

What type of company is Orchestra BioMed?

Orchestra BioMed is a biomedical company focused on high-impact technologies.

What are forward-looking statements in the press release?

They refer to expectations about the company's future development and opportunities.

Last updated: Jun 1, 2023